摘要
目的 研究环丙沙星、左氧氟沙星及加替沙星(均为氟喹诺酮类抗生素)对临床分离的鲍曼不动杆菌敏感株及其环丙沙星诱导的突变株的防耐药突变浓度(MPC),比较防耐药突变能力.方法 用环丙沙星琼脂平板,筛选鲍曼不动杆菌临床分离株的突变株;用琼脂平板稀释法,测定各实验菌株的最低抑菌浓度(MIC)和MPC.结果 加替沙星和左氧氟沙星对临床分离株及其突变株的 MPC 低于环丙沙星;对临床分离株的 MPC,加替沙星和左氧氟沙星均为0.25 μg·mL-1,环丙沙星为2 μg·mL-1;对突变株,前者为1～8μg·mL-1,后者为 4～32μg·mL-1.结论 对临床分离的鲍曼不动杆菌敏感株及其环丙沙星诱导的突变株,加替沙星和左氧氟沙星限制其耐药突变株选择的能力强于环丙沙星;建议临床对环丙沙星敏感的鲍曼不动杆菌,要避免这 3 种氟喹诺酮的单药治疗.
Objective To measure mutant prevention concentration (MPC) of fluoroquinolones for Baumannii acinetobacter and its ciprofloxacin induced mutant strains. To evaluate the capacity of fluoroquinolones for restricting the selection of resistant mutant. Methods The mutant strains of Baumannii acinetobacter which was separated from clinical sample were selected by ciprofloxacin. The minimum inhibition concentrations (MIC) and MPC of the fluoroquinolones for the clinical strain and mutant strains were determined by agar plates dilution method.Results MPC of gatifloxacin and levofloxacin were lower than those of ciprofloxacin for the clinical strain and its mutant strains. For the clinical strain,the MPC of gatifloxacin and levofloxacin were 0.25 μg·mL-1, MPC of ciprofloxacin was 2 μg·mL-1. For the mutant strains the MPC were 1~8 μg·mL-1and 4~32 μg·mL-1,respectively.Conclusion The capacities of restricting selection of resistant mutant of gatifloxacin and levofloxacin were stranger than that of ciprofloxacin for Baumannii acinetobacter and its ciprofloxacin induced mutant strains. But combined with pharmacokinetic parameters, in clinical it is adviced that not to use one of the 3 fluoroquinolones singly to treat the Baumannii acinetobacter even if it is sensitive to ciprofloxacin.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2007年第6期420-423,共4页
The Chinese Journal of Clinical Pharmacology
关键词
鲍曼不动杆菌
氟喹诺酮
防耐药突变浓度
Baumannii acinetobacter
fluoroquinolones
mutant prevention concentration
